Please enable JavaScript to continue using this application.

Compare $KLRA vs $ZYME | Chartloom

Compare

$KLRA vs $ZYME

Kailera Therapeutics Inc · Zymeworks Inc

KLRA

Kailera Therapeutics Inc

ZYME

Zymeworks Inc

Compare $KLRA vs $ZYME

Comparing Kailera Therapeutics Inc and Zymeworks Inc

KLRAKailera Therapeutics Inc

ZYMEZymeworks Inc

KLRAKailera Therapeutics Inc

Market cap

$1.50B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-55.3%

52W performance

-55.3%

FCF yield

0.0%

ZYMEZymeworks Inc

Market cap

$1.85B

P/E (TTM)

—

Forward P/E (NTM)

8.20x

Forward P/S (NTM)

3.91x

Rev growth (TTM)

-69.8%

YTD performance

-3.1%

52W performance

54.6%

FCF yield

-6.5%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

KLRA

ZYME

Detailed metrics comparison

KLRA

Kailera Therapeutics Inc

ZYME

Zymeworks Inc

Market Cap

KLRA$1.50B

ZYME$1.85B

Enterprise Value

KLRA$1.37B

ZYME$1.92B

Price

KLRA$11.61

ZYME$25.79

P/E Ratio

KLRAN/A

ZYMEN/A

P/S Ratio

KLRA0.00x

ZYME49.73x

EV/Sales

KLRA0.00x

ZYME51.70x

EV/EBITDA

KLRA0.00x

ZYME9.18x

P/B Ratio

KLRA1.20x

ZYME23.27x

P/FCF Ratio

KLRAN/A

ZYMEN/A

EV/FCF

KLRA0.00x

ZYME-15.91x

PEG Ratio

KLRAN/A

ZYMEN/A

Forward P/E (NTM)

KLRAN/A

ZYME8.20x

Forward P/S (NTM)

KLRAN/A

ZYME3.91x

Revenue (TTM)

KLRA$0

ZYME$37M

Revenue Growth (YoY)

KLRAN/A

ZYME-69.8%

Forward Rev Growth

KLRA275.8%

ZYME-15.2%

Gross Margin (TTM)

KLRA0.0%

ZYME0.0%

Operating Margin (TTM)

KLRA0.0%

ZYME0.0%

EBITDA Margin (TTM)

KLRA0.0%

ZYME-405.8%

Net Margin (TTM)

KLRA0.0%

ZYME-404.0%

FCF Margin (TTM)

KLRAN/A

ZYME-325.1%

Net Income (TTM)

KLRA$-190M

ZYME$-150M

FCF (TTM)

KLRA$0

ZYME$-121M

EPS (TTM)

KLRA-$1.86

ZYME-$2.05

ROE (TTM)

KLRA0.0%

ZYME-7207.0%

ROA (TTM)

KLRA0.0%

ZYME-3706.0%

ROIC (TTM)

KLRA0.0%

ZYME-4505.0%

Cash

KLRA$130M

ZYME$179M

Debt

KLRA$0

ZYME$253M

Net Cash/Debt

KLRA$130M

ZYME$-73M

Current Ratio (TTM)

KLRA11.11x

ZYME6.32x

Quick Ratio (TTM)

KLRA11.04x

ZYME5.86x

Debt/Equity (TTM)

KLRA0.00x

ZYME3.14x

Debt/Assets (TTM)

KLRA0.0%

ZYME0.0%

Interest Coverage (TTM)

KLRAN/A

ZYMEN/A

Net Debt/EBITDA (TTM)

KLRA0.00x

ZYME0.00x

Beta

KLRA2.22

ZYME1.32

52W Performance

KLRA-55.3%

ZYME54.6%

YTD Performance

KLRA-55.3%

ZYME-3.1%

% from 52W High

KLRA-58.9%

ZYME-17.7%

% from 52W Low

KLRA19.0%

ZYME61.2%

Asset Turnover (TTM)

KLRA0.00x

ZYME0.09x

FCF Yield (TTM)

KLRA0.0%

ZYME-6.5%

Earnings Yield (TTM)

KLRA-12.6%

ZYME-8.1%

Dividend Yield (TTM)

KLRAN/A

ZYMEN/A

Rule of 40

KLRA0.0

ZYME-394.8

EV/GP/RG

KLRAN/A

ZYMEN/A

Ticker research

View KLRA research View ZYME research

Metric	KLRA Kailera Therapeutics Inc	ZYME Zymeworks Inc
Market & Valuation
Market Cap	$1.50B	$1.85B
Enterprise Value	$1.37B	$1.92B
Price	$11.61	$25.79
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	49.73x
EV/Sales	0.00x	51.70x
EV/EBITDA	0.00x	9.18x
P/B Ratio	1.20x	23.27x
P/FCF Ratio	N/A	N/A
EV/FCF	0.00x	-15.91x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	8.20x
Forward P/S (NTM)	N/A	3.91x
Revenue & Growth
Revenue (TTM)	$0	$37M
Revenue Growth (YoY)	N/A	-69.8%
Forward Rev Growth	275.8%	-15.2%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-405.8%
Net Margin (TTM)	0.0%	-404.0%
FCF Margin (TTM)	N/A	-325.1%
Net Income (TTM)	$-190M	$-150M
FCF (TTM)	$0	$-121M
EPS (TTM)	-$1.86	-$2.05
ROE (TTM)	0.0%	-7207.0%
ROA (TTM)	0.0%	-3706.0%
ROIC (TTM)	0.0%	-4505.0%
Financial Health
Cash	$130M	$179M
Debt	$0	$253M
Net Cash/Debt	$130M	$-73M
Current Ratio (TTM)	11.11x	6.32x
Quick Ratio (TTM)	11.04x	5.86x
Debt/Equity (TTM)	0.00x	3.14x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.22	1.32
52W Performance	-55.3%	54.6%
YTD Performance	-55.3%	-3.1%
% from 52W High	-58.9%	-17.7%
% from 52W Low	19.0%	61.2%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.09x
FCF Yield (TTM)	0.0%	-6.5%
Earnings Yield (TTM)	-12.6%	-8.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-394.8
EV/GP/RG	N/A	N/A
Ticker research	View KLRA research	View ZYME research

Valuation

P/S Ratio

KLRA

0.00x

ZYME

49.73x

EV/FCF

ZYME

-15.91x

KLRA

0.00x

Growth & revenue

Revenue Growth TTM

ZYME

-69.8%

Forward Revenue Growth

KLRA

275.8%

ZYME

-15.2%

Profitability & performance

Gross Margin

KLRA

0.0%

ZYME

0.0%

ROE

KLRA

0.0%

ZYME

-7207.0%

FCF Yield %

KLRA

0.0%

ZYME

-6.5%

52-Week Performance

ZYME

54.6%

KLRA

-55.3%

Detailed metrics comparison

KLRA

Kailera Therapeutics Inc

ZYME

Zymeworks Inc

Market Cap

KLRA$1.50B

ZYME$1.85B

Enterprise Value

KLRA$1.37B

ZYME$1.92B

Price

KLRA$11.61

ZYME$25.79

P/E Ratio

KLRAN/A

ZYMEN/A

P/S Ratio

KLRA0.00x

ZYME49.73x

EV/Sales

KLRA0.00x

ZYME51.70x

EV/EBITDA

KLRA0.00x

ZYME9.18x

P/B Ratio

KLRA1.20x

ZYME23.27x

P/FCF Ratio

KLRAN/A

ZYMEN/A

EV/FCF

KLRA0.00x

ZYME-15.91x

PEG Ratio

KLRAN/A

ZYMEN/A

Forward P/E (NTM)

KLRAN/A

ZYME8.20x

Forward P/S (NTM)

KLRAN/A

ZYME3.91x

Revenue (TTM)

KLRA$0

ZYME$37M

Revenue Growth (YoY)

KLRAN/A

ZYME-69.8%

Forward Rev Growth

KLRA275.8%

ZYME-15.2%

Gross Margin (TTM)

KLRA0.0%

ZYME0.0%

Operating Margin (TTM)

KLRA0.0%

ZYME0.0%

EBITDA Margin (TTM)

KLRA0.0%

ZYME-405.8%

Net Margin (TTM)

KLRA0.0%

ZYME-404.0%

FCF Margin (TTM)

KLRAN/A

ZYME-325.1%

Net Income (TTM)

KLRA$-190M

ZYME$-150M

FCF (TTM)

KLRA$0

ZYME$-121M

EPS (TTM)

KLRA-$1.86

ZYME-$2.05

ROE (TTM)

KLRA0.0%

ZYME-7207.0%

ROA (TTM)

KLRA0.0%

ZYME-3706.0%

ROIC (TTM)

KLRA0.0%

ZYME-4505.0%

Cash

KLRA$130M

ZYME$179M

Debt

KLRA$0

ZYME$253M

Net Cash/Debt

KLRA$130M

ZYME$-73M

Current Ratio (TTM)

KLRA11.11x

ZYME6.32x

Quick Ratio (TTM)

KLRA11.04x

ZYME5.86x

Debt/Equity (TTM)

KLRA0.00x

ZYME3.14x

Debt/Assets (TTM)

KLRA0.0%

ZYME0.0%

Interest Coverage (TTM)

KLRAN/A

ZYMEN/A

Net Debt/EBITDA (TTM)

KLRA0.00x

ZYME0.00x

Beta

KLRA2.22

ZYME1.32

52W Performance

KLRA-55.3%

ZYME54.6%

YTD Performance

KLRA-55.3%

ZYME-3.1%

% from 52W High

KLRA-58.9%

ZYME-17.7%

% from 52W Low

KLRA19.0%

ZYME61.2%

Asset Turnover (TTM)

KLRA0.00x

ZYME0.09x

FCF Yield (TTM)

KLRA0.0%

ZYME-6.5%

Earnings Yield (TTM)

KLRA-12.6%

ZYME-8.1%

Dividend Yield (TTM)

KLRAN/A

ZYMEN/A

Rule of 40

KLRA0.0

ZYME-394.8

EV/GP/RG

KLRAN/A

ZYMEN/A

Ticker research

View KLRA research View ZYME research

Metric	KLRA Kailera Therapeutics Inc	ZYME Zymeworks Inc
Market & Valuation
Market Cap	$1.50B	$1.85B
Enterprise Value	$1.37B	$1.92B
Price	$11.61	$25.79
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	49.73x
EV/Sales	0.00x	51.70x
EV/EBITDA	0.00x	9.18x
P/B Ratio	1.20x	23.27x
P/FCF Ratio	N/A	N/A
EV/FCF	0.00x	-15.91x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	8.20x
Forward P/S (NTM)	N/A	3.91x
Revenue & Growth
Revenue (TTM)	$0	$37M
Revenue Growth (YoY)	N/A	-69.8%
Forward Rev Growth	275.8%	-15.2%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-405.8%
Net Margin (TTM)	0.0%	-404.0%
FCF Margin (TTM)	N/A	-325.1%
Net Income (TTM)	$-190M	$-150M
FCF (TTM)	$0	$-121M
EPS (TTM)	-$1.86	-$2.05
ROE (TTM)	0.0%	-7207.0%
ROA (TTM)	0.0%	-3706.0%
ROIC (TTM)	0.0%	-4505.0%
Financial Health
Cash	$130M	$179M
Debt	$0	$253M
Net Cash/Debt	$130M	$-73M
Current Ratio (TTM)	11.11x	6.32x
Quick Ratio (TTM)	11.04x	5.86x
Debt/Equity (TTM)	0.00x	3.14x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.22	1.32
52W Performance	-55.3%	54.6%
YTD Performance	-55.3%	-3.1%
% from 52W High	-58.9%	-17.7%
% from 52W Low	19.0%	61.2%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.09x
FCF Yield (TTM)	0.0%	-6.5%
Earnings Yield (TTM)	-12.6%	-8.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-394.8
EV/GP/RG	N/A	N/A
Ticker research	View KLRA research	View ZYME research